Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.63 USD
-0.05 (-2.98%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $1.64 +0.01 (0.61%) 7:28 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Earnings News For ESPR
-
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
-
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
-
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
-
Esperion Therapeutics: Q2 Earnings Snapshot
-
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
-
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
-
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
-
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
-
Esperion Therapeutics: Q1 Earnings Snapshot
-
Esperion Reports First Quarter 2024 Financial Results
-
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
-
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
-
Esperion Therapeutics: Q4 Earnings Snapshot
-
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
-
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
-
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?
-
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
-
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
-
Esperion Therapeutics: Q3 Earnings Snapshot
-
Esperion Reports Third Quarter 2023 Financial Results
-
Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report?
-
Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues
-
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates